Dr. Mel Lobo

Dr Mel Lobo is a consultant physician with a special interest in cardiovascular medicine and in particular hypertension. He is the Director of the internationally renowned Bart’s and The London Hypertension Clinic which has been recognised as a Hypertension Centre of Excellence by the European Society of Hypertension. Dr Lobo is an accredited Clinical Hypertension Specialist of the European Society of Hypertension and sees in excess of 2000 hypertension-related consultations per year in both inpatient and outpatient settings.

Dr Lobo undertakes NHS practice in St Bartholomew’s and The Royal London Hospital Trust, one of the oldest teaching hospitals in Western Europe. He runs the Coronary Care Unit and the Cardiovascular Medicine team in the Royal London Hospital and continues to participate in receiving unselected emergency admissions on the acute medical take in his capacity as an accredited specialist in general internal medicine

Medical School:

University of Manchester Medical School

Qualifications:

Bachelor of Medicine and Bachelor of Surgery MB ChB. 1989

Post Graduate:

• Member of the Royal College of Physicians (MRCP London) 1994
• PhD Thesis (Vascular Biology), University of London 2000

Registration:

The General Medical Council (No: 3325506)

Specialty:

• Clinical Hypertension Specialist of the European Society of Hypertension
• Cardiovascular and General Internal Medicine
• Clinical Pharmacology & Therapeutics

Professional Memberships:

• Member of the Royal College of Physicians, London
• Member of the British Hypertension Society
• Member of the British Pharmacological Society

Current Appointments Public (NHS) Hospitals:

• Consultant Physician,
  St Bartholomew’s and The Royal London Hospitals’ Trust

Private Hospital Visiting/Admitting Rights:

• The London Clinic, Harley Street
• London Bridge Hospital
• BMI London Independent Hospital

His particular interests are:

• All forms of hypertension and in particular secondary hypertension and low renin essential hypertension
• Developing protocols to improve the management of resistant hypertension
• Improving medicines safety and avoiding adverse drug reactions/interactions
• Improving community-based management of patients at high risk of cardiovascular disease